SG11202007178VA - Compositions and methods of enhancing 5-hydroxytryptophan bioavailability - Google Patents

Compositions and methods of enhancing 5-hydroxytryptophan bioavailability

Info

Publication number
SG11202007178VA
SG11202007178VA SG11202007178VA SG11202007178VA SG11202007178VA SG 11202007178V A SG11202007178V A SG 11202007178VA SG 11202007178V A SG11202007178V A SG 11202007178VA SG 11202007178V A SG11202007178V A SG 11202007178VA SG 11202007178V A SG11202007178V A SG 11202007178VA
Authority
SG
Singapore
Prior art keywords
hydroxytryptophan
bioavailability
enhancing
compositions
methods
Prior art date
Application number
SG11202007178VA
Other languages
English (en)
Inventor
Jacob P R Jacobsen
Marc G Caron
Original Assignee
Univ Duke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Duke filed Critical Univ Duke
Publication of SG11202007178VA publication Critical patent/SG11202007178VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202007178VA 2018-01-29 2019-01-28 Compositions and methods of enhancing 5-hydroxytryptophan bioavailability SG11202007178VA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862623073P 2018-01-29 2018-01-29
US201862743816P 2018-10-10 2018-10-10
PCT/US2019/015391 WO2019148087A1 (en) 2018-01-29 2019-01-28 Compositions and methods of enhancing 5-hydroxytryptophan bioavailability

Publications (1)

Publication Number Publication Date
SG11202007178VA true SG11202007178VA (en) 2020-08-28

Family

ID=67395723

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202007178VA SG11202007178VA (en) 2018-01-29 2019-01-28 Compositions and methods of enhancing 5-hydroxytryptophan bioavailability

Country Status (14)

Country Link
US (1) US11337963B2 (cg-RX-API-DMAC7.html)
EP (1) EP3746058B1 (cg-RX-API-DMAC7.html)
JP (2) JP7758320B2 (cg-RX-API-DMAC7.html)
KR (2) KR20250025043A (cg-RX-API-DMAC7.html)
CN (1) CN111902137A (cg-RX-API-DMAC7.html)
AU (1) AU2019211458B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020015068A2 (cg-RX-API-DMAC7.html)
ES (1) ES2948788T3 (cg-RX-API-DMAC7.html)
IL (1) IL276059B2 (cg-RX-API-DMAC7.html)
MX (1) MX2020007760A (cg-RX-API-DMAC7.html)
MY (1) MY209656A (cg-RX-API-DMAC7.html)
RU (1) RU2020125170A (cg-RX-API-DMAC7.html)
SG (1) SG11202007178VA (cg-RX-API-DMAC7.html)
WO (1) WO2019148087A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12409163B2 (en) * 2021-07-30 2025-09-09 Evecxia Therapeutics, Inc. Method of enhancing 5-hydroxytryptophan (5-HTP) exposure
AU2022320730A1 (en) 2021-07-30 2024-03-14 Evecxia Therapeutics, Inc. 5-hydroxytryptophan gastroretentive dosage forms
US11779567B2 (en) 2021-10-14 2023-10-10 Evecxia Therapeutics, Inc. Method for optimizing 5-hydroxytryptamine function in the brain for therapeutic purposes
DE102022103658A1 (de) * 2022-02-16 2023-08-17 Joachim Kamprad Arzneimittelzusammensetzung enthaltend L-Tryptophan (L-Try) und L-5-Hydroxytryptophan (5-HTP) sowie einen peripheren Abbauhemmer
WO2024148354A1 (en) 2023-01-06 2024-07-11 Evecxia Therapeutics, Inc. A method of enhancing 5-hydroxytryptophan (5-htp) exposure
CN119074695B (zh) * 2024-08-29 2026-07-24 江南大学 一种可提高脑内5-ht水平的口服缓释制剂及其在改善失眠中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4658038A (en) 1982-10-07 1987-04-14 Research Foundation For Mental Hygiene, Inc. N-acylated 5-hydroxytryptophan amide derivatives
FR2654931B1 (fr) 1989-11-24 1993-08-27 Trouillas Paul Compositions pharmaceutiques possedant une activite sur l'ataxie et les troubles de l'equilibre, cerebelleux ou autres, de toutes origines, comprenant l'association de l-5-hydroxytryptophane et de carbidopa.
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
ATE302597T1 (de) 1997-06-06 2005-09-15 Depomed Inc Im magen verweilende orale dosierungsformen von wasserlöslichen arzneistoffen mit kontrollierter freisetzung
US6207699B1 (en) * 1999-06-18 2001-03-27 Richard Brian Rothman Pharmaceutical combinations for treating obesity and food craving
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US20060013875A1 (en) 2002-05-29 2006-01-19 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
AU2003293423A1 (en) 2002-12-06 2004-06-30 Xenoport, Inc. Carbidopa prodrugs and uses thereof
EP1751312A4 (en) 2004-05-21 2010-01-27 Univ Duke POLYMORPHISM IN TRYPTOPHAN HYDROXYLASE 2 REGULATING BRAIN SEROTONIN SYNTHESIS
US20070213370A1 (en) 2005-11-18 2007-09-13 H. Lundbeck A/S 5-HTP Combination Therapy
US8969400B2 (en) 2007-10-01 2015-03-03 Duke University Pharmaceutical compositions of 5-hydroxytryptophan and serotonin-enhancing compound
ES2740360T3 (es) 2008-08-15 2020-02-05 Assertio Therapeutics Inc Composiciones farmacéuticas de retención gástrica para el tratamiento y la prevención de trastornos del SNC
CA2788675C (en) * 2010-02-05 2018-01-16 Phosphagenics Limited Carrier composition
WO2012054815A1 (en) * 2010-10-22 2012-04-26 Duke University Slow-release formulations of 5-hydroxytryptophan as an adjunct to pro-serotonergic therapies
CN103554005A (zh) 2013-11-22 2014-02-05 长沙理工大学 一种左旋5-羟基色氨酸的简便合成新方法

Also Published As

Publication number Publication date
JP2021511365A (ja) 2021-05-06
EP3746058A1 (en) 2020-12-09
IL276059B1 (en) 2024-04-01
KR20250025043A (ko) 2025-02-20
BR112020015068A2 (pt) 2021-01-05
EP3746058C0 (en) 2023-06-07
JP2023153871A (ja) 2023-10-18
US20210346345A1 (en) 2021-11-11
EP3746058A4 (en) 2021-12-22
US11337963B2 (en) 2022-05-24
KR20200116110A (ko) 2020-10-08
EP3746058B1 (en) 2023-06-07
IL276059B2 (en) 2024-08-01
CN111902137A (zh) 2020-11-06
ES2948788T3 (es) 2023-09-19
MY209656A (en) 2025-07-29
WO2019148087A1 (en) 2019-08-01
AU2019211458B2 (en) 2024-08-29
IL276059A (en) 2020-08-31
AU2019211458A1 (en) 2020-08-06
CA3089068A1 (en) 2019-08-01
JP7758320B2 (ja) 2025-10-22
MX2020007760A (es) 2020-10-28
RU2020125170A (ru) 2022-02-28

Similar Documents

Publication Publication Date Title
IL274276A (en) CASZ preparations and methods of use
GB2582100B (en) CAS12C Compositions and methods of use
IL276059A (en) Compositions and methods for improving 5-hydroxytryptophan bioavailability
IL268970A (en) New preparations and methods
IL275694A (en) Unnatural nucleotide compounds and methods of using them
IL266398A (en) Liver organoid preparations, methods for their production and their uses
IL280709A (en) Converted indoles and methods of using them
ZA201708067B (en) Compositions and methods for degradation of misfolded proteins
ZA201906169B (en) Synthekine compositions and methods of use
GB202201859D0 (en) Novel methods and compositions
IL276135A (en) Preparations and methods of use
IL269590A (en) Methods and compositions for reducing immunogenicity
IL274524A (en) Preparations and methods for aquaculture
IL276592A (en) History of Subtirum
ZA202100780B (en) Bismuth-thiol compositions and methods of use
LT3573620T (lt) Kompozicijos, skirtos hipertenzijos gydymui
IL266840A (en) History of tyrosine and preparations containing them
EP3509614A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF LAFORA DISEASE
GB2568562B (en) Moldable compositions and methods of using thereof
PT3867446T (pt) Composições de adesivo yankee e métodos de utilização destas composições
IL272737B2 (en) Devices and methods for the preparation of a nutritional formula
SG11202002351SA (en) Poloxamer compositions and methods of making and using same
IL283703A (en) A polymorphic form of meisoindigo and a different formulation of meisoindigo
PL3445730T3 (pl) Makrokompozyty i kompozycje z kamienia i szkła oraz sposoby wytwarzania
EP3313399A4 (en) COMPOSITIONS AND METHODS FOR INHIBITING RIT1